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Abstract
Imatinib, a tyrosine kinase inhibitor has revolutionized the therapy of Philadelphia chromosome
positive chronic myeloid leukemia. Side effects of imatinib include grade 1-4 hepatotoxicity in a subset
of patients. We report the case of a 46-year-old male with chronic myeloid leukemia, who developed
hepatic hemosiderosis during treatment with imatinib. After ruling out the established congenital and
acquired causes of hepatic hemosiderosis, we attribute this to a possible side effect of imatinib
therapy. This condition was successfully treated with periodic phlebotomy thus precluding
discontinuation of imatinib. To our knowledge, this is the first report of hepatic hemosiderosis
most likely consequent to imatinib therapy.
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative
disorder characterized by the presence of Philadelphia
chromosome, which is the translocated 9:22 chromosome
giving rise to constitutively active BCR-Abl fusion protein
[1,2].
Imatinib mesylate, an orally administered tyrosine-kinase
inhibitor, targets this fusion protein and produces anti-
proliferative and pro-apoptotic effects on the neoplastic
cells containing the translocation. Reported hepatic side
effects observed with imatinib range from mild elevation
of transaminases, to acute fulminant hepatitis and fatal
liver failure [3-4,7]. We report the case of a 46-year-old
male with CML who developed high levels of transami-
nases secondary to hemosiderosis likely induced by
imatinib therapy. Intereference by imatinib in the iron
metabolism is also suggested by a recent report of
intradermal hemosiderosis consequent to imatinib
therapy [6].
Case presentation
This is the case of a 46-year-old Caucasian male who came
to us with complaints of mild fatigue and unexplained
weight loss of about 28 pounds over 8 month period.
Physical exam was remarkable for splenomegaly without
any lymphadenopathy. Labs revealed leucocytosis with a
white cell count of 63.3 x 103/ml. A manual differential
count of peripheral blood smear showed neutrophil 44%,
lymphocyte 1%, monocyte 3%, eosinophil 1%, basophil
6%, bands 22%, metamyelocyte 14%, myelocyte 9%.
Following diagnosis of chronic phase CML by bone
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marrow biopsy the patient was started on 400mg imatinib
daily. Within a month of treatment, his white counts
dropped from about 63,000/ml to 12,000/ml. Cytogenetic
tests showed typical 9:22 translocation in all 20 banded
cells examined. 4 of these cells also had an additional
Philadelphia chromosome indicating a possible clonal
evolution suggestive of accelerated or blast phase crisis of
the disease. Thus the dosage of imatinib was increased to
600 mg daily. In another couple of weeks, his white cell
count dropped to 3400/ml alongwith a drop of hemoglo-
bin from 13.4 gm/dL to 11.1 gm/dL and platelets from
239,000/ ml to 57,000/ ml. Further drop of WBC count to
1800/ ml over the next 10 days warranted a reduction of
imatinib dosage from 600 mg to 400 mg daily. His white
count however continued to drop to 1500/ ml when he
became febrile and was advised to discontinue imatinib
for a couple weeks. His fever resolved with antibiotics and
following 2 weeks of discontinuation of imatinib, his
white count was back up at 5100/ ml, with absolute
neutrophil count of 2700/ ml, hemoglobin 13.9 and
platelets 190,000/ ml. The patient was restarted on
400 mg of imatinib daily. He tolerated this dose well for
2 weeks without any drop in cell counts and the imatinib
dosage was increased to 500 mg daily. This dose was
continued thereafter.
By the first 9 months following initial diagnosis the
patient was able to achieve and maintain a complete
molecular remission as evident by quantitative RT-PCR
(reverse transcriptase polymerase chain reaction) of BCR-
Abl transcript. His splenomegaly had resolved clinically. It
was concerning however that his liver function tests
became increasingly abnormal. Although his baseline
liver function tests were within normal limits prior to
treatment initiation, his ALT (alanine aminotransferase)
was noted to be mildly elevated one month after the start
of imatinib therapy, became normal after nine months
and then again progressively increased to markedly high
levels at eighteen months (Figure 1). On the contrary, the
AST (aspartate aminotransferase) was first elevated at
eighteen months of imatinib therapy and then progres-
sively increased albeit to lesser extents than ALT (Figure 1).
At 22 months following imatinib therapy, the AST was at
about 3 times the upper limit of reference range while ALT
level peaked at approximately 5 times the upper limit of
reference range. The strikingly elevated liver enzymes with
a normal alkaline phosphatase and bilirubin were
suggestive of hepatocellular injury in absence of a
cholestatic etiology. With an effort to address the problem
without having to discontinue imatinib therapy, we
decided to investigate in to the etiology of increased
transaminases. Patient’s occasional alcohol intake history,
normal viral hepatitis serologic studies, alpha fetoprotein
level, ceruloplasmin level, magnetic resonance imaging of
the abdomen were helpful in ruling out alcoholic liver
disease, viral hepatitis, focal nodular hyperplasia, malig-
nant hepatic involvement, Budd-Chiari syndrome and
Wilsons disease. Finally, on patient’s consent, a liver
biopsy with iron stain revealed prominent iron deposition
within hepatic parenchymal cells and portal areas as well
as mild portal fibrosis (Figure 2). Consistently, the ferritin
levels were found to be markedly elevated, while
transferrin saturation levels were within normal limits
(Figure 1). These findings prompted the genetic analysis
for hereditary hemochromatosis (C282Y and H63D loci),
which turned out to be negative. Following discussion
with patient, phlebotomy was initiated which dramati-
cally brought the liver enzymes back to normal levels
(Figure 1). Following the first phlebotomy, the imatinib
dosage was increased to 600 mg daily and continued
thereafter. Patient had the initial two phlebotomies
3 months apart followed by every 6 months. Patient’s
liver functions remained within normal limits until his
recent follow up at 42 months after initiating imatinib
therapy and roughly 15 months following initiation of
phlebotomy. Hence the patient was able to maintain
imatinib treatment with continued molecular remission,
taking recourse only to periodic phlebotomy at 3-6 month
intervals. Patient tolerated phlebotomy well with no side
effects or anemia.
Figure 1. Imatinib causes elevated liver transaminases.
Temporal relationship of imatinib therapy with markedly
elevated ALT and AST levels secondary to hepatic
hemosiderosis. The concurrently elevated serum ferritin level
and the time of initiation of treatment with phlebotomy are
indicated. Patient was on imatinib 400-600 mg daily during the
whole period of time except a brief discontinuation of 2
weeks in the second month due to neutropenic fever. The
dosage of imatinib is indicated. The break in the line indicates
the 2-week period during which imatinib was discontinued for
neutropenic fever.
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Discussion
The discovery of the BCR-Abl translocation in CML
culminated in the realization of the dream of targeted
therapy in cancer by the small molecule tyrosine kinase
inhibitor imatinib [9]. The recently reported result of
6-year Phase III clinical trial confirms the durability of
response to imatinib in addition to the declining incidence
of adverse events over time [1]. Currently, indications of
imatinib include the treatment of CML and gastrointestinal
stromal tumor (GIST).Most patients with newly diagnosed
chronic phase CML experience complete cytogenetic
responses with imatinib treatment, however continuation
of treatment is required to prevent molecular or cytoge-
netic relapse [8]. According to the literature, recurrent liver
toxicity was the second most common reason for
permanent discontinuation of imatinib therapy [4,5]. Of
all the patients undergoing treatment with imatinib, only a
minor subset reportedly exhibits hepatotoxicity [10-14].
Grade 1 elevation in transaminases was observed in up to
6-12% of patients and grade3/4 in 3-8% of patients
receiving imatinib therapy [3-5]. The cases of suspected
imatinib induced hepatotoxicity responded to disconti-
nuation of treatment either promptly or in a delayed
manner [4]. In some cases including a case of imatinib
induced immune hepatitis, corticosteroids were helpful in
resolving the hepatotoxicity and enabling resumption or
continuation of imatinib treatment [4,10-15].
In the absence of transfusional iron overload, hepatic
hemosiderosis in the aforesaid case with normal transfer-
rin saturation is a possible consequence of imatinib
therapy. The elevated liver enzymes were not associated
with any discernible infectious or inflammatory condition
hence making hemophagocytosis a less likely possibility.
While anti-nuclear antibody (ANA) was elevated at 2.3 OD
ratio (ref range <1.5 OD ratio), anti-mitochondrial anti-
body, anti-smooth muscle antibody and alfa-1-antitrypsin
antibody were negative. It seems unlikely that the
mechanism of iron overload is a result of increased iron
absorption or simply a higher intake in way of iron being
an ingredient in imatinib mesylate tablets since there was
no evidence of iron overload in any other organs including
heart, spleen or pancreas. Whether it was secondary to
interference of imatinib with heme metabolism in the
reticuloendothelial cells remains to be elucidated. In this
case report, wemade an effort to understand the pathology
behind imatinib induced hepatotoxicity and were able to
treat the condition successfully by periodic phlebotomy.
This is relatively safer than using measures as corticoster-
oid therapy or stopping imatinib treatment as have been
shown to be effective in reversing other forms of imatinib
induced hepatotoxicity. Imatinib induced disturbance in
the iron homeostasis is also suggested by a recent report of
intradermal hemosiderosis as a possible consequence to
imatinib therapy, lending further support to our conclu-
sion that the observed hepatic hemosiderosis is most likely
a consequence imatinib therapy [6].
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Figure 2. Hepatic hemosiderosis is a likely consequence of
imatinib treatment. Liver biopsy with iron stain revealing
prominent iron deposition within hepatic parenchymal cells
and portal areas (indicated).
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